Spotlight Stories
-
Finance And Funding Outlook 2024: Additional Responses
12/14/2023
Additional 2024 Outlook responses from biopharma leaders on finance and funding topics.
-
Manufacturing And Supply Chain: Making Space Between A Rock And A Hard Place
12/1/2023
Biopharmaceutical companies can’t afford to halt production lines due to manufacturing violations next year. Manufacturing and supply chain processes will require fresh thinking and flexibility in 2024.
-
Executive Outlook: Converting Innovative Science Into Predictable Returns
12/1/2023
Executives at Big Pharma and small biotech will be rewarded in 2024 if they can find new ways to develop and commercialize drugs in the context of an unforgiving investment, payer, and regulatory landscape.
-
Finance And Funding: Anticipating Improvement, Planning For Uncertainty
12/1/2023
Executives responding to this year’s finance and funding outlook questions are optimistic about the potential for a turnaround in 2024.
-
Biopharma’s Eminent Challenges In 2024 — Inside & Out
12/1/2023
A baker’s dozen of biopharma CEOs answer a call to prioritize and describe challenges they expect to face in the coming year.
-
Building A Business Model For Novel Antibiotics
11/1/2023
In the challenging development space for novel antibiotics, Spero Therapeutics is using partnership, external validation, and formulation science to develop drugs treating bacterial infections both rare and common.
-
The Power Couple Behind Krystal Biotech
11/1/2023
Krish and Krishnan, the husband-and-wife team that founded and leads Krystal Biotech, cleared a path to market for the first ever topical and redosable gene therapy.
-
Heading Back Home To The Heart
11/1/2023
Cardior Pharmaceuticals, led by CEO and cofounder Claudia Ulbrich, is developing what may be a much broader approach to heart failure, one that seeks to restore the diseased heart to its natural healthy state.
-
Life Biosciences Grows Up: A Q&A With Jerry McLaughlin
10/2/2023
Through the boom and bust of anti-aging buzz cycles, Life Biosciences has continued its focus on epigenetic reprogramming with an increasingly focused pipeline and development strategy.
-
Using AI To Find And Develop Safer Medicines
10/2/2023
Montai Health CEO Margo Georgiadis is using what she’s learned at McKinsey, Discover, Google, Mattel, and Ancestry to reinvent drug discovery and development, with a focus on long-term safety.